Publications by authors named "Suzanne Hendrix"

Claim this Profile
D
Development of composite scales for assessing disease progression and treatment effects among patients with Parkinson's disease in a clinical trial setting.
Gil L'Italien, Basia Rogula, Lauren C Powell, Michele Potashman, Samuel P Dickson, Suzanne Hendrix

Parkinsonism Relat Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials.
Samuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, Laura Nisenbaum, Howard M Fillit, Suzanne B Hendrix

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.
Susan Abushakra, P Murali Doraiswamy, John A Hey, Duygu Tosun, Frederik Barkhof, Suzanne Hendrix

CNS Drugs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial.
Benjamin Haaland, Samuel P Dickson, Agustin Fernández Santana, Rudolph E Tanzi, Bruno Dubois, Suzanne B Hendrix

J Alzheimers Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease.
Garrett B Duncan, Samuel P Dickson, Johanne M Kaplan, Samuel B Johnson, Tyler M Duke, Suzanne B Hendrix

Alzheimers Dement (N Y)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.
Bradley T Wyman, Dan Adams, Suzanne Hendrix, Jeffrey Groves, Wayne Croft

Neurotherapeutics· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease.
Mieke Nuytten, Marieke Voets, Eveline Debroux, Katrien Princen, Lentel Pringels, Suzanne Hendrix

Alzheimers Dement· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson's Disease.
Gil L'Italien, Basia Rogula, Lauren Powell, Michele Potashman, Samuel P Dickson, Suzanne Hendrix

Neurol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease.
Valentina R Garbarino, Juan Pablo Palavicini, Justin Melendez, Nicolas R Barthelemy, Yingxin He, Suzanne Hendrix

Neurotherapeutics· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysis.
Suzanne B Hendrix, Mary Sano, Constantine Lyketsos, Paul B Rosenberg, Anton P Porsteinsson

Int Psychogeriatr· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time saved in activities of daily living and whole-brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease.
Ralph Kern, Benjamin Haaland, Jessie Nicodemus-Johnson, Samuel Dickson, Matthew Morgan, Suzanne Hendrix

Alzheimers Dement (N Y)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia.
Evan Bailey, Han Phan, Ayesha Ahmad, Janet Thomas, Elizabeth G Ames, Suzanne B Hendrix

J Clin Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation.
Jeffrey Cummings, Michael Gold, Mark Mintun, Michael Irizarry, Andrew von Eschenbach, Suzanne Hendrix

J Prev Alzheimers Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies.
Samuel P Dickson, Craig H Mallinckrodt, Basia Rogula, Lauren C Powell, Michele H Potashman, Suzanne B Hendrix

Neurol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of SCACOMS, a Composite Scale for Assessing Disease Progression and Treatment Effects in Spinocerebellar Ataxia.
Gilbert L'Italien, Evan Popoff, Basia Rogula, Lauren Powell, Michele Potashman, Suzanne Hendrix

Cerebellum· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease.
Yan Hu, Min Cho, Pallavi Sachdev, Jeffrey Dage, Suzanne Hendrix

Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease.
Steven E Arnold, Suzanne Hendrix, Jessie Nicodemus-Johnson, Newman Knowlton, Victoria J Williams

Alzheimers Dement (N Y)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer's disease.
Mihály Hajós, Alyssa Boasso, Evan Hempel, Monika Shpokayte, Alex Konisky, Suzanne Hendrix

Front Neurol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study.
Hui Jing Yu, Samuel P Dickson, Pei-Ning Wang, Ming-Jang Chiu, Chin-Chang Huang, Suzanne B Hendrix

EBioMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review.
Samuel P Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton, Suzanne B Hendrix

Alzheimers Res Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Alette M Wessels, Ellen B Dennehy, Sherie A Dowsett, Samuel P Dickson, Suzanne B Hendrix

Neurol Clin Pract· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.
Roos J Jutten, Kathryn V Papp, Suzanne Hendrix, Noel Ellison, Jessica B Langbaum

Alzheimers Dement· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes.
Sabrina Paganoni, Claire Watkins, Matthew Cawson, Suzanne Hendrix, Samuel P Dickson

Muscle Nerve· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Sabrina Paganoni, Suzanne Hendrix, Samuel P Dickson, Newman Knowlton, James D Berry

J Neurol Neurosurg Psychiatry· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Craig M McDonald, Eduardo Marbán, Suzanne Hendrix, Nathaniel Hogan, Rachel Ruckdeschel Smith

Lancet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis